Adam Gefvert, CFA
Contributor since: 2011
Latest Articles
If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits
Holders Of Great Northern Iron Ore Will Lose 30% Of Their Money In 7 Months
The Professional Diversity Network's New Hard-Selling Strategy To Get Members Likely Won't Work
Northwest Bio - You Can See This Data, But Not That Data
The Odds Of El Pollo Loco Falling Below $30 Are Very High
Limelight Networks Is In Terminal Decline, $1.50 Price Target
Why It Will Take Years For Uni-Pixel To Reach Production, If Ever, Meanwhile Executives Will Still Get Rich
Expect A 30%+ Decline In Underperforming eLong When The Buyout Rumors Turn Out To Be False
Uni-Pixel Still Struggling To Advance From A Lab Experiment To A Sellable Product
Great Northern Iron Ore Properties Will Likely Fall To $15 Soon After The June 26th Ex-Dividend Date
Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains
Maxim's $22 Price Target On Achillion Is Far From Realistic
Why Big Pharma Has No Interest In Achillion's 'Me Too' Hepatitis C Drug
Gevo, An Extremely Overvalued Ethanol Plant, Has Failed With Its Isobutanol Project
Retrophin's Press Releases Have A Lot Of Sugarcoating
Khosla Is Going To Rip The Rug Underneath KIOR Shareholders When It Files For Bankruptcy
Did Bankruptcy-Bound KiOR Fail To Receive Khosla's Expected Investment?
Quantum Fuel System's Business Expansion Is By Necessity, Not Choice
Capstone Turbine Shareholders Have More Pain Ahead
VisionChina - Chinese Bus Advertising Is A Tough Business To Make A Profit
You On Demand Is Likely A Zero
Are LeapFrog Tablets Going The Way Of The Dodo?
Capstone Turbine's Stock Is More Bloated Than Plug Power's Ever Was
Sky-mobi Is Dominating China's Low-Cost Smartphone App Market
Audience Cancelled 2 Major Investor Conferences - Is It In Takeover Talks?
Microvision's Pico Projector Technology Has Some Big Disadvantages Compared To The Competition
With No Significant Revenue Streams In Sight, Microvision Will Continue Falling
ServiceNow's Market Cap Has Gotten Ahead Of Its Future Growth Story
Organovo Currently Has Nothing In The Works For Tissue Implantation -- Its Main Value Driver
2014 Will Be A Tough Year For Renewable Energy Group And Other Biodiesel Producers
Will Unilife Be A Tiny Unmet Needs Developer Or A Manufacturing Powerhouse?
An Analysis Of Unilife's Products Shows A Weak Business Case